Drug Trial Radar · NCT07190300
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
181
Planned (sponsor's estimate)
Start
Jan 13, 2026
Primary completion
Aug 2, 2032
Study completion Aug 2, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s) for expansion (RDE) of tulmimetostat in combination with darolutamide or abiraterone. Phase II is designed to further evaluate the efficacy and safety of tulmimetostat in combination with darolutamide compared with darolutamide alone in participants with mHSPC.
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
TulmimetostatDrug
Tulmimetostat is an oral dual EZH1/EZH2 inhibitor administered once daily. In Phase I, escalating dose levels will be evaluated in combination with darolutamide or abiraterone. In Phase II, one or two dose levels selected from Phase I will be evaluated in combination with darolutamide.
DarolutamideDrug
Darolutamide 600 mg administered orally twice daily (BID).
AbirateroneDrug
Abiraterone 1000 mg administered orally once daily (QD) in combination with prednisone/prednisolone according to local prescribing information.
Prednisone/PrednisoloneDrug
Oral corticosteroid administered with abiraterone in Phase I Group B according to local prescribing information.
Androgen Deprivation Therapy (ADT)Drug
Background therapy consisting of a gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior orchiectomy to maintain castrate testosterone levels (\<50 ng/dL \[\<1.7 nmol/L\]). All participants will continue ADT throughout study participation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I (Group A and Group B): Dose-limiting toxicities (DLTs)Time frame: From the first dose of study treatment through the end of Cycle 1, up to 28 days
- Phase I (Group A and Group B): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
- Phase I (Group A and Group B): Number of Participants with dose adjustmentsTime frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
- Phase I (Group A and Group B): Dose IntensityTime frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
- Phase I (Group A and Group B): Duration of exposure to each study drugTime frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
- Phase II (Group A): Prostate-Specific Antigen (PSA) response rate of < 0.2 ng/mL at Month 6Time frame: At Month 6, with confirmation by a second prostate-specific antigen assessment performed at least 3 weeks later
Locations
31 sites in 14 countries. Site status is shown where the registry gives one.
Univ of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Uni Of Iowa Hospitals And Clinics
Iowa City, Iowa · Recruiting
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Wichita Urology Group PA
Wichita, Kansas · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Medical University of South Carolina MUSC
Charleston, South Carolina · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Novartis Investigative Site
Camperdown, New South Wales, Australia · Withdrawn
Novartis Investigative Site
Wollongong, New South Wales, Australia · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Guangzhou, China · Recruiting
Novartis Investigative Site
Créteil, France · Recruiting
Novartis Investigative Site
Lille, France · Recruiting
Novartis Investigative Site
Nantes, France · Recruiting
Novartis Investigative Site
Essen, Germany · Recruiting
Novartis Investigative Site
Jena, Thuringia, Germany · Recruiting
Novartis Investigative Site
Hong Kong, Hong Kong · Recruiting
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Szeged, Hungary · Recruiting
Novartis Investigative Site
Rozzano, MI, Italy · Recruiting
Novartis Investigative Site
Verona, VR, Italy · Active not recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Ankara, Sihhiye Altindag, Turkey (Türkiye) · Recruiting
Novartis Investigative Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.